nach oben

01.05.2013 | INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTON EDITOR)

Update on Treatment of Inclusion Body Myositis

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Degenerative mechanisms such as protein accumulation and vacuolar transformation in the skeletal muscle distinguish inclusion body myositis (IBM) from other inflammatory myopathies. IBM is particularly common in patients over the age of 50 years and inevitably leads to progressive muscle weakness and atrophy. Conventional immunotherapies, albeit effective in other forms of myositis, seem to have only a transient or no beneficial effect on disease progression of IBM. So far, no established evidence-based treatment exists and therapy recommendations are based on expert opinion. Recent clinical trials using monoclonal antibodies such as alemtuzumab or etanercept have failed to demonstrate efficacy. Different treatment studies with drugs that aim at degenerative disease mechanisms are planned or ongoing. This review aims to provide an overview of the current treatment options for IBM.

Dalakas MC. Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2008;2(8):437–47.CrossRef

Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009;19(3):493–506.PubMedCrossRef

Schmidt J, Dalakas MC. Inclusion-body myositis in the elderly: an update. Aging Health. 2010;6(6):687–94.CrossRef

Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immnosuppressive therapy. Medicine (Baltimore). 1993;72(4):224–35.

Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379–87.PubMedCrossRef

Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother. 2009;10(7):1183–90.PubMedCrossRef

Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302–4.PubMedCrossRef

Badrising UA, Maat-Schieman ML, Ferrari MC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51(3):369–72.PubMedCrossRef

Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19(9):1385–9.PubMed

10.

Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61(2):260–2.PubMedCrossRef

11.

Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci. 2001;185(2):199–22.CrossRef

12.

Chaudhry V, Cornblath DR, Griffin JW, et al. Myocophenolate mofetil: a safe and promising immunosuppressant in neuromuscular disease. Neurology. 2001;56(1):94–6.PubMedCrossRef

13.

Quartuccio L, De Marchi G, Scott CA, et al. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol. 2007;25(2):246–51.PubMed

14.

Kelly Jr JJ, Madoc-Jones H, Adelman LS, et al. Total body irradiation not effective in inclusion body myositis. Neurology. 1986;36(9):1264–6.PubMedCrossRef

15.

Dau PC. Leukocytapharesis in inclusion body myositis. J Clin Apher. 1987;3(3):167–70.PubMedCrossRef

16.

Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57(9):1566–70.CrossRef

17.

Muscle Study Group. Randomized pilot trial of high-dose betaINF1a in patients with inclusion body myositis. Neurology. 2004;63(4):718–20.CrossRef

18.

Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S123–4.PubMedCrossRef

19.

Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43(5):876–9.PubMedCrossRef

20.

Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48(3):712–6.PubMedCrossRef

21.

Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58(2):326.PubMedCrossRef

22.

Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247(1):22–8.PubMedCrossRef

23.

Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56(3):323–7.PubMedCrossRef

24.

• Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol. 2012;30(6); 838-42. This study provides data of long-term treatment with immunoglobulin in patients with IBM. PubMed

25.

Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536–44.PubMedCrossRef

26.

•• Beneviste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11): 3176-84. Data on the natural course of IBM were obtained in a large patient cohort.CrossRef

27.

•• Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11);3167-75. Data on the natural course of IBM were obtained in a large patient cohort. PubMedCrossRef

28.

Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trail of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081–7.PubMedCrossRef

29.

• Sancricca C, Mora M, Ricci E, et al. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci. 2011;32(5): 841-7. This is an interesting study with a non-immunosuppressant. PubMedCrossRef

30.

Yamada T, Minohara M, Imaiso Y, et al. High-dose vitamin C therapy for inclusion body myositis. Fukuoka Igaku Zasshi. 2001;92(4):99–104.PubMed

31.

•• Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opinion Rheumatol. 2012;24(2): 201-7. This review gives a thorough overview of the literature and published data on exercise and physical training in inflammatory myopathies and evaluates the overall safety and efficacy. CrossRef

32.

Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve. 1997;20(1):1242–8.PubMedCrossRef

33.

Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003;35(1):31–5.PubMedCrossRef

34.

Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10(4):178–84.PubMedCrossRef

35.

Gualano B, Ugrinowitsch C, Neves M Jr. et al. Vascular occlusion training for inclusion body myositis: a novel therapeutic approach. J Vis Exp. 2010;5;(40).

36.

• Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87(11):883–9. This is a helpful overview on dysphagia in IBM.

37.

Malandraki GA, Kaufman A, Hind J, et al. The effects of lingual intervention in a patient with inclusion body myositis and Sjögren’s syndrome: a longitudinal case study. Arch Phys Med Rehabil. 2012;93(8):1469–75.PubMedCrossRef

38.

Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with Dysphagia. Clin Med Insights Case Rep. 2013;6:1–7.PubMedCrossRef

39.

Riminton DS, Chambers ST, Parkin PJ, et al. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43(6):1241–3.PubMedCrossRef

40.

Darrow DH, Hoffman HT, Barnes GJ, Willey CA. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg. 1992;118(3):313–7.PubMedCrossRef

41.

Verma A, Bradley WG, Adesina AM, et al. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve. 1991;14(5):470–3.PubMedCrossRef

42.

Wintzen AR, Bots GT, de Bakker HM, et al. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51(12):1542–5.PubMedCrossRef

43.

Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18(6):397–9.PubMed

44.

Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol. 2008;64(1):15–24.PubMedCrossRef

45.

• Zschüntzsch J, Voss J, Creus K, et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. Arthritis Rheum. 2012;64(12): 4094-103. This study suggests that the insufficient block of NO-stress is a major reason for the lack of efficacy of prednisone and IVIG. PubMedCrossRef

46.

• Allenbach Y, Beneviste O, Decostre V, et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord. 2012;22(11): 980-6. This study provides helpful data for the choice of appropriate outcome measures in future treatment trials on IBM. PubMedCrossRef

Titel: Update on Treatment of Inclusion Body Myositis
Publikationsdatum: 01.05.2013
Erschienen in: Current Rheumatology Reports / Ausgabe 5/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0329-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Update on Treatment of Inclusion Body Myositis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin